CDC Reports Safety Findings for Bivalent COVID-19 Vaccine Boosters
In a recent report released by the CDC, a panel of health experts revealed that early safety findings from v-safe and the Vaccine Adverse Event Reporting System for bivalent booster doses administered to individuals aged 12 years and older during the first 7 weeks of vaccine availability are comparable to those previously described for monovalent vaccine booster vaccines. Read more.

Investigational Cancer Vaccine Announced by Merck and Moderna
Moderna, Inc. and Merck recently announced that Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement. Personalized cancer vaccines are created to prime the immune system so that a patient can generate a tailored antitumor response to their tumor mutation signature. Read more.

Updated Data for Pfizer-BioNTech Omicron BA.4/BA.5 Bivalent Booster
Pfizer Inc. and BioNTech SE recently announced updated data from a phase II/III clinical trial demonstrating a strong, neutralizing immune response 1 month after a 30-mcg booster dose of the companies’ Omicron BA.4/BA.5–adapted bivalent COVID-19 vaccine. Immune responses against BA.4/BA.5 sublineages were considerably greater for those who received the bivalent vaccine compared with the companies’ original COVID-19 vaccine. Read more.